Setting Breakpoints

Breakpoints for phenotypic antimicrobial susceptibility testing have been determined by breakpoint committees and as part of regulatory processes for the approval of new drugs since the 1970s. Knowledge of dosage, modes of administration, target infections and clinical outcome when wild type organisms of defined species are treated, pharmacokinetics and pharmacodynamics of the agent, MIC distributions and ECOFFs (epidemiological cut-off values), resistance mechanisms, zone diameter distributions, are all used in the breakpoint-setting process. There is no mathematical algorithm in which all of these can be fitted to obtain a breakpoint. Instead it is a scientific process where the importance and influence of the various components are weighed against each other.

Document

Link

Setting breakpoints for new antimicrobial agents

SOP 1.5, 9 May 2025

Download PDF

Review and revision of antimicrobial breakpoints

SOP 3.4, 6 May 2025

Download PDF

Implications of breakpoints splitting the wild type and/or resistant populations

12 May 2016

Download PDF

Publications

Title

Link

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach

9 December 2011

Go to article

How to: ECOFFs - the why, the how, and the don'ts of EUCAST epidemiological cutoff values

24 February 2022

Go to article

Contact

Looking for more information? Get in touch with an EUCAST representative today!

Contact form